Medtronic (MDT)

The sleeper story is the diabetes spinoff structure creating a permanent 3-4% EPS tailwind through share retirement rather than typical one-time buyback, with Martha explicitly saying they'll grow earnings from that higher base. The obvious headline is PFA acceleration, but the real constraint is supply chain execution - they've solved Affera manufacturing but now need to prove the catheter volume ramp. Most revealing quote: Thierry admitting tariff mitigation relies on 'focused efforts from teams' with no specifics, suggesting they're hoping for policy relief rather than executing concrete plans. My view changes if Q1 shows CAS growth actually accelerating above 30% with improving catheter mix, or if they provide specific tariff mitigation actions with dollar amounts.